Drug Type Small molecule drug |
Synonyms Metformin/repaglinide, PrandiMet, Repaglinide and Metformin Hydrochloride + [4] |
Mechanism PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), Potassium channel blockers, VGKCs blockers(Voltage-gated potassium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (23 Jun 2008), |
Regulation- |
Molecular FormulaC27H36N2O4 |
InChIKeyFAEKWTJYAYMJKF-QHCPKHFHSA-N |
CAS Registry135062-02-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | CN | 01 Jun 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Preclinical | CN | 01 Aug 2009 | |
Diabetes Mellitus, Type 2 | Preclinical | US | 23 Jun 2008 |